Literature DB >> 16470081

Is the development of diabetes with antihypertensive therapy a problem?--Pro.

Paolo Verdecchia1, Fabio Angeli, Gianpaolo Reboldi, Roberto Gattobigio.   

Abstract

Some questions about new-onset diabetes (NOD) must still be completely addressed: 1) its incidence; 2) the possible association between NOD and some classes of antihypertensive drugs; and 3) its prognostic impact. It is well known that diuretics and beta blockers can increase plasma glucose and, in available hypertension trials, diuretics and beta blockers caused a higher incidence of NOD than new antihypertensive drugs. NOD heralds a high risk of major cardiovascular events, but the absolute difference between old and new drugs was too small to significantly drive the differences in cardiovascular event rates between the two groups of treatment. This evidence suggests a judicious use of drugs more frequently associated with NOD in subjects at high risk of diabetes (impaired fasting glucose, overweight, family history of diabetes, low high-density lipoprotein cholesterol levels). The lowest effective dose of these drugs should be used, plasma glucose should be checked periodically, and concomitant lifestyle measures to prevent diabetes should be implemented with resolution.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16470081      PMCID: PMC8109692          DOI: 10.1111/j.1524-6175.2006.04587.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  29 in total

1.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

Authors:  L Hansson; L H Lindholm; L Niskanen; J Lanke; T Hedner; A Niklason; K Luomanmäki; B Dahlöf; U de Faire; C Mörlin; B E Karlberg; P O Wester; J E Björck
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

2.  New-onset diabetes in the hypertension treatment trials: a point of view.

Authors:  Marvin Moser
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-11       Impact factor: 3.738

3.  Diabetes and cardiovascular events in hypertensive patients.

Authors:  M H Alderman; H Cohen; S Madhavan
Journal:  Hypertension       Date:  1999-05       Impact factor: 10.190

4.  Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study.

Authors:  Kristina Dunder; Lars Lind; Björn Zethelius; Lars Berglund; Hans Lithell
Journal:  BMJ       Date:  2003-03-29

5.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

Authors:  Lindon M H Wing; Christopher M Reid; Philip Ryan; Lawrence J Beilin; Mark A Brown; Garry L R Jennings; Colin I Johnston; John J McNeil; Graham J Macdonald; John E Marley; Trefor O Morgan; Malcolm J West
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

6.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

8.  Diabetes and cardiovascular risk factors: the Framingham study.

Authors:  W B Kannel; D L McGee
Journal:  Circulation       Date:  1979-01       Impact factor: 29.690

9.  Impaired fasting glucose, blood pressure and cardiovascular disease mortality.

Authors:  Patrick Henry; Frédérique Thomas; Athanase Benetos; Louis Guize
Journal:  Hypertension       Date:  2002-10       Impact factor: 10.190

10.  Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.

Authors:  Koon Teo; Salim Yusuf; Peter Sleight; Craig Anderson; Farouk Mookadam; Barbara Ramos; Lutz Hilbrich; Janice Pogue; Helmut Schumacher
Journal:  Am Heart J       Date:  2004-07       Impact factor: 4.749

View more
  3 in total

Review 1.  Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects.

Authors:  Jason H Karnes; Rhonda M Cooper-DeHoff
Journal:  Expert Rev Cardiovasc Ther       Date:  2009-06

Review 2.  Is new-onset diabetes of clinical significance in treated hypertensive patients?--Con.

Authors:  Marvin Moser
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-02       Impact factor: 3.738

3.  The potential role of clinical pharmacy services in patients with cardiovascular diseases.

Authors:  Azita Hajhossein Talasaz
Journal:  J Tehran Heart Cent       Date:  2012-05-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.